Cargando…

Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis

AIM: Several consensus guidelines recommend against routine brain imaging at diagnosis of T1-3N0 non-small cell lung cancer (NSCLC). METHODS: From the Surveillance, Epidemiology and End Results registry, patients with pathologically confirmed T1-3N0 NSCLC were identified. Risks of brain metastases a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milano, Michael T, Bates, James E, Budnik, Justin, Qiu, Haoming, Hardy, Sara, Cummings, Michael A, Baumgart, Megan A, Maggiore, Ronald J, Mulford, Deborah A, Usuki, Kenneth Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110582/ https://www.ncbi.nlm.nih.gov/pubmed/32256710 http://dx.doi.org/10.2217/lmt-2019-0010

Ejemplares similares

Patterns of recurrence after intracranial stereotactic radiosurgery for brain-only metastases from non-small cell lung cancer and the impact of upfront thoracic therapy with synchronous presentation
por: Bergsma, Derek P., et al.
Publicado: (2022)

Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review
por: Komisarof, Justin, et al.
Publicado: (2021)

Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review
por: Komisarof, Justin, et al.
Publicado: (2021)

Severe radiation-induced leukoencephalopathy: Case report and literature review
por: Cummings, Michael, et al.
Publicado: (2016)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Patient-reported impact of symptoms in lung cancer (PRISM-LC)
por: Varma, Anika, et al.
Publicado: (2023)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

DNA alkylation and interstrand cross-linking by treosulfan
por: Hartley, J A, et al.
Publicado: (1999)

A comprehensive evaluation of advanced dose calculation algorithms for brain stereotactic radiosurgery
por: Yoon, Jihyung, et al.
Publicado: (2023)

Cutaneous metastases as a presenting sign of metastatic NSCLC
por: McSweeney, William T, et al.
Publicado: (2019)

The road of NSCLC stem cells toward bone metastases
por: Bertolini, Giulia, et al.
Publicado: (2022)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

ASCO 2018 NSCLC highlights—combination therapy is key
por: Gamerith, Gabriele, et al.
Publicado: (2018)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

ASCO 2020 non-small lung cancer (NSCLC) personal highlights
por: Horvath, Lena, et al.
Publicado: (2021)

Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells
por: Kuzumaki, N, et al.
Publicado: (2012)

Oligoprogression in non-small cell lung cancer: a narrative review
por: Nguyen, Katarina T., et al.
Publicado: (2022)

Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases
por: Schoenmaekers, Janna J.A. O., et al.
Publicado: (2022)

Is higher lymphocyte count a potential strategy for preventing chronic kidney disease in patients receiving long-term dasatinib treatment?
por: Nakayama, Hirokazu, et al.
Publicado: (2023)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery
por: Gao, Hong Xiang, et al.
Publicado: (2018)

Predictive effect of DCE-MRI and DWI in brain metastases from NSCLC
por: Ye, Chengyu, et al.
Publicado: (2021)

MLTI-03. The relevance of the count of brain metastases for treatment and outcome in NSCLC
por: Reinecke, David, et al.
Publicado: (2021)

Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
por: Nicoś, Marcin, et al.
Publicado: (2022)

Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective
por: Lee, Chee Khoon, et al.
Publicado: (2023)

Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay
por: Lema, Diego A, et al.
Publicado: (2020)

Alternative drugs go global: possible lead and/ or mercury intoxication from imported natural health products and a need for scientifically evaluated poisoning monitoring from environmental exposures
por: Budnik, Lygia Therese, et al.
Publicado: (2016)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
por: Sun, Dantong, et al.
Publicado: (2020)

Simple immobilization for stereotactic radiotherapy aimed at pelvic metastases
por: Janssen, Jorinde, et al.
Publicado: (2023)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
por: Gajra, Ajeet, et al.
Publicado: (2018)

Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases
por: Cai, Linbo, et al.
Publicado: (2016)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC
por: Ikarashi, Daiki, et al.
Publicado: (2021)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Value of CT Radiomics and Clinical Features in Predicting Bone Metastases in Patients with NSCLC
por: Chen, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lf939ec1c0gm4kfelelgn73pnt